AbbVie has started enrollment of a projected 1600 participants in 6 new international Phase 3 clinical trials evaluating a once-daily regimen of its investigational NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 for people with hepatitis C virus (HCV) genotypes 1 through 6, the company recently announced.
